Pacific Edge bladder cancer test validation bodes well for US market sales

Pacific Edge bladder cancer test validation bodes well for US market sales
By Peter Kerr Aug. 6 (BusinessDesk) - Dunedin-based DNA diagnostic test business Pacific Edge has received independent clinical confirmation that its bladder cancer detection test is at least as effective as other methods. The validation in the American Journal of Urology could be worth up to $100 million a year in five years’ time for Pacific Edge’s Cxbladder test, the company said. Chief executive David Darling says the peer-reviewed validation that the company’s urine-based test has the ability to detect nearly all tumours of concern to...